Panleukopenia-like syndrome of FeLV caused by co-infection with FeLV and feline panleukopenia virus.
To study the effect of interferon on feline leukemia virus (FeLV) infection, 30 specific pathogen free (SPF) cats were infected with the apathogenic FeLV A Glasgow. Unexpectedly, between 5 and 8 weeks after FeLV infection, all 19 cats with persistent FeLV infection but not the FeLV-negative cats died from a panleukopenia-like syndrome. No feline panleukopenia virus (FPLV) antigen was found in feces by latex agglutination, enzyme-linked immunosorbent assay (ELISA) or immunoelectron microscopy. No enteropathogenic bacteria were found. Histopathology revealed changes resembling those of FPLV infection such as destruction of crypts and pancytopenia of bone marrow. Neither clinical signs nor seroconversion to FPLV could be induced by transmitting intestinal extracts to two SPF cats. However, FPLV antigen was demonstrated by immunofluorescence assay in intestinal cryostat sections of diseased animals. FPLV could also be demonstrated in intestinal extracts by immunoelectron microscopy, by latex agglutination and ELISA after anti-FPLV antibodies were removed from immune-complexed FPLV by ultracentrifugation over a CsCl gradient at pH 2.0. From these experiments it was concluded that the panleukopenia-like syndrome of FeLV may not be caused by FeLV alone but at least in some cases by co-infection with FeLV and FPLV. In addition, some form of 'cooperation' between FeLV and FPLV must be postulated because neither virus alone induced symptoms.
Lutz
H
H
Department of Veterinary Medicine, University of Zurich, Switzerland.
Castelli
I
I
Ehrensperger
F
F
Pospischil
A
A
Rosskopf
M
M
Siegl
G
G
Grob
M
M
Martinod
S
S
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000032:analysis; D002415:Cats; D002499:Centrifugation, Density Gradient / Q000662:veterinary; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005243:Feces / Q000382:microbiology; D016181:Feline Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000276:immunology / Q000473:pathology; D005254:Feline Panleukopenia / Q000209:etiology* / Q000276:immunology / Q000473:pathology / Q000635:transmission; D028301:Feline Panleukopenia Virus / Q000276:immunology* / Q000302:isolation & purification / Q000648:ultrastructure; D005455:Fluorescent Antibody Technique / Q000662:veterinary; D007370:Interferon Type I / Q000494:pharmacology; D007841:Latex Fixation Tests / Q000662:veterinary; D005256:Leukemia Virus, Feline / Q000276:immunology* / Q000302:isolation & purification / Q000648:ultrastructure; D008221:Lymphoid Tissue / Q000473:pathology / Q000821:virology; D016253:Microscopy, Immunoelectron / Q000662:veterinary; D011994:Recombinant Proteins; D013047:Specific Pathogen-Free Organisms; D013577:Syndrome; D014766:Viremia / Q000276:immunology / Q000662:veterinary
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007370:Interferon Type I; D011994:Recombinant Proteins